Adcentrx Therapeutics

Company Drug

Adcentrx Therapeutics Receives NMPA IND Clearance for STEAP1-Targeting ADC ADRX-0405 in Advanced Solid Tumors

Fineline Cube Jun 9, 2026

Adcentrx Therapeutics announced today that China’s National Medical Products Administration (NMPA) has cleared the company’s...

Company Drug

Jikeshu (Sebaloxavir Marboxil) Receives NMPA Approval for Adolescent Influenza Treatment, Expanding Single-Dose Category 1 Antiviral Franchise

Company Drug

CSPC Pharmaceutical Receives FDA Clearance for Once-Monthly Semaglutide SYH9017 in Weight Management, Challenging Weekly GLP-1 Standard

Company Drug

Lepu Medical Receives TGA Approval for Phase I Trial of Dual-Targeting siRNA MWX205 Against PCSK9 and ANGPTL3 in Australia

Company Deals

Everest Medicines Secures Asia-Pacific Rights to Vcare Pharma’s Next-Generation P2Y12 Inhibitor Sumecigrel in $3M Licensing Deal